When building your watch list, look for stocks with an 80 or higher RS Rating. Tarsus Pharmaceuticals just met that criteria with a new score of 87.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners typically have an RS Rating of above 80 as they launch their biggest price moves.
Tarsus Pharmaceuticals is working on a cup without handle with a 53.89 entry. See if it can break out in heavy trade.
The company reported 0% earnings growth last quarter. Revenue rose 152%.
Tarsus Pharmaceuticals holds the No. 39 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
